CATALYST PHARMACEUTICALS, INC. 4

Chief Legal Officer Brian Elsbernd had 242,501 shares of common stock, multiple in-the-money stock option grants, and several RSU awards in Catalyst Pharmaceuticals, Inc. cashed out or cancelled for cash at the $31.50 per-share merger price in connection with the Angelini Pharma acquisition.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chief Legal Officer Brian Elsbernd had all of his equity awards—common stock, stock options, and restricted stock units—disposed of in connection with the cash acquisition of Catalyst by Angelini Pharma S.p.A. at $31.50 per share. A total of 242,501 shares of common stock were cancelled at the $31.50 merger price. In addition, multiple tranches of fully vested options to purchase common stock with exercise prices ranging from $3.42 to $22.77 per share and expiration dates from December 2026 through November 2032 were cancelled and converted into the right to receive cash equal to the intrinsic value per option (the $31.50 merger price minus the option strike price) multiplied by the number of option shares. Likewise, several tranches of restricted stock units scheduled to vest between December 2026 and November 2028 were accelerated, cancelled, and converted into the right to receive cash equal to $31.50 per underlying share. Following these transactions, Elsbernd no longer holds equity in Catalyst Pharmaceuticals as the securities were fully cashed out under the merger terms.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000176

Alert Tier

6